Description

TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function[1].—Cancer-programmed cell death–C109H151F3N34O34S2—-[1]Chunlin Li, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018 Feb;6(2):178-188.—-2602.70—-O=C(N1[C@@H](CCC1)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(NCC(NCC(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CS)NC([C@@H](NC([C@H](CS)NC([C@@H](NC([C@@H](NC([C@H](CO)NC([C@H](C)NC([C@@H](NC([C@H](CCC(N)=O)NC(CNC([C@@H](N)CO)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)CC4=CN=CN4)=O)=O)CC5=CNC6=CC=CC=C56)=O)=O)CC7=CNC8=CC=CC=C78)=O)=O.O=C(C(F)(F)F)O–Cancer–10 mM in DMSO–PD-1/PD-L1—-Immunology/Inflammation–Peptides